MedTrace Logo

A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis

NCT04342715 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 216

Last updated 2025-07-24

No results posted yet for this study

Summary

ImmStat@Cure is a multicentre observational study designed to assess the immune status of patients before and after treatment for visceral leishmaniasis. Forty patients and 30 controls will be recruited per site. The follow-up period is 6 months from the end of treatment.

Conditions

  • Visceral Leishmaniasis

Interventions

DRUG

Sodium stibogluconate / paramomycin

Treatment with Sodium stibogluconate / paramomycin

Sponsors & Collaborators

  • University of Gondar

    collaborator OTHER

  • Kenya Medical Research Institute

    collaborator OTHER

  • Makerere University

    collaborator OTHER

  • University of Khartoum

    collaborator OTHER

  • European Vaccine Initiative

    collaborator OTHER

  • European and Developing Countries Clinical Trials Partnership (EDCTP)

    collaborator OTHER_GOV

  • University of York

    lead OTHER

Principal Investigators

  • Paul Kaye, PhD · University of York

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-22
Primary Completion
2025-05-31
Completion
2026-03-31

Countries

  • Kenya

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04342715 on ClinicalTrials.gov